

# An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis

NCT06941376

---

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Pennsylvania
Enrollment	20 participants

## Key Eligibility Criteria

---

### Inclusion (35)

- A. e18 years of age
- B. Must fulfill McAdam's or Damiani's or Michet's Criteria Diagnostic Criteria for Relapsing Polychondritis McAdam's Criteria (1976)
- e 3riteria out of 6 of the following:
  - Bilateral auricular chondritis
  - Non-erosive seronegative polyarthritis
- ... and 30 more (see full listing online)

### Exclusion (36)

- A. Severe disease manifestations within the past 28 days, including:
  - Severe airway inflammation with supplemental oxygen requirement, tracheostomy, airway stenting, ventilation. Patients with prior history of severe airway disease, who currently have damage will be eligible if they have mild- moderate active disease within the past 60 days at the time of enrollment.
  - Central nervous system (CNS) disease (meningitis, encephalitis, optic neuritis) requiring hospitalization/ treatment with intravenous methylprednisolone/ cyclophosphamide.
  - Cardiac disease (symptomatic valve dysfunction, heart failure) requiring active treatment for heart failure/ hospitalization/ consideration for surgery.
  - Severe ophthalmologic manifestations: severe scleritis, uveitis, retinal vasculitis, optic neuritis which is imminently vision threatening.
- ... and 31 more (see full listing online)

## Locations (1 total)

---

University of Pennsylvania, Philadelphia, Pennsylvania, United States

---

<https://clinicaltrials.gov/study/NCT06941376>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).